Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (443)	5/17/1999 11:45:00 AM
From: mauser96	Read Replies (1) \| Respond to of 717

More good news. Phase 2 study on Lutrin for metastatic carcinoma of chest wall is in, click on "News". All of these patients had multiple chemotherapy failures and most had radiation failures, so they represented a very hard to treat group. Reading between the lines, it seems to me that Lutrin is an easier treatment to do than most, side effects are limited to the area treated rather than whole body, and therefore this could become the first treatment tried ,rather than the last. Also, though it wasn't tested, it might work best with minimal side effects if given as a set of smaller dose treatments rather than one big one. This phase 2 study has determined the optimum time relationship between giving the Lutrin, and the light, so future studies should show even better results. This form of breast cancer isn't that common, so the potential market is limited.